BETHLEHEM, Pa.--(BUSINESS WIRE)--Agno Pharma (“Agno”), a US-based, global pharmaceutical contract development and manufacturing organization, announced today that it will acquire the Lubrizol Particle Sciences Inc. business (“Particle Sciences”). The acquisition includes the drug product formulation technology behind the Particle Sciences Inc.

宾夕法尼亚州伯利恒——（商业新闻短讯）——总部位于美国的全球制药合同开发和制造组织Agno Pharma（“Agno”）今天宣布，它将收购路博润粒子科学公司（Lubrizol Particle Sciences Inc.）的业务（“粒子科学”）。此次收购包括粒子科学公司背后的药品配方技术。

business as well as the Bethlehem, PA, development and manufacturing site with approximately 65 employees..

业务以及宾夕法尼亚州伯利恒的开发和制造场地，约有65名员工。。

Founded in 1991, Particle Sciences specializes in pre-clinical and clinical stage drug product formulation and offers a comprehensive suite of supporting services, including analytic, bioanalytic, physical characterization, and manufacturing. The Company has deep expertise in dealing with poorly soluble and highly potent compounds in both sterile and non-sterile environments..

粒子科学成立于1991年，专门从事临床前和临床阶段的药物制剂，并提供一整套支持服务，包括分析，生物分析，物理表征和制造。该公司在无菌和非无菌环境中处理难溶性和高效化合物方面拥有丰富的专业知识。。

The acquisition of Particle Sciences will provide Agno with expanded capability and capacity to extend its drug product formulation and clinical manufacturing services to its customers globally. Following the acquisition, Agno plans to further invest upon clinical scale manufacturing services from sterile liquid manufacturing and filling services to micronization of sterile powder filling capabilities.

收购Particle Sciences将为Agno提供更大的能力，将其药品配方和临床制造服务扩展到全球客户。收购后，Agno计划进一步投资于临床规模的制造服务，从无菌液体制造和灌装服务到无菌粉末灌装能力的微粉化。

The acquisition underscores Agno's commitment to providing an end-to-end solution for its high-value customers globally across the pharmaceutical sector..

此次收购突显了Agno致力于为全球制药行业的高价值客户提供端到端解决方案。。

About Agno Pharma

关于Agno Pharma

Agno Pharma is a global small molecule CDMO supplying critical intermediates, active pharmaceutical ingredients (APIs), highly potent APIs, sterile APIs, and sterile drug product formulations to large and medium-sized pharmaceutical, biotech and CDMO customers. Founded in 2004, Agno has process development and US-FDA inspected GMP-compliant manufacturing facilities with sterile suspension injectable manufacturing capabilities.

Agno Pharma是一家全球小分子CDMO，为大中型制药、生物技术和CDMO客户提供关键中间体、活性药物成分（API）、高效API、无菌API和无菌药物产品配方。Agno成立于2004年，拥有工艺开发和美国食品和药物管理局（US-FDA）检查的符合GMP的生产设施，具有无菌悬浮注射生产能力。

In addition, Agno has established a drug product formulation research and development laboratory for complex injectables. Agno has invested in its people and facilities and established a broad spectrum of service capabilities throughout the entire drug development and commercialization process. Agno has an excellent track record in the delivery of commercial stage scale-up solutions to its customers in North America and Europe.

此外，Agno还建立了一个用于复杂注射剂的药品配方研究和开发实验室。Agno在其人员和设施方面进行了投资，并在整个药物开发和商业化过程中建立了广泛的服务能力。Agno在向北美和欧洲的客户提供商业舞台放大解决方案方面有着良好的业绩记录。

http://agnopharma.com/.

http://agnopharma.com/.